PMCPA Case
| Case | AUTH/3550/7/21 |
|---|---|
| Parties | Health professional v Lundbeck |
| Product | Vyepti (eptinezumab) |
| Setting | Migraine Trust International Symposium (MTIS) virtual symposium (live) and on-demand hosting on MTIS website |
| Main issue | Promotion of eptinezumab prior to UK marketing authorisation; ambiguous sponsorship declaration; on-demand content not properly restricted |
| Applicable Code year | 2019 |
| Complaint received | 29 July 2021 |
| Case completed | 26 July 2022 |
| Appeal | No appeal |
| Breach clauses | 2; 3.1; 9.1; 9.10 |
| No breach clauses | 12.1 (and no breaches found in relation to the Vimeo video link) |
| Sanctions | Undertaking received; Additional sanctions: Advertisement |
| Notes on scope | UK delegates were 18.2% (315) and the largest country group; invitation e-shots were sent to all delegates including UK HCPs |
Download the full case report (PDF)
Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory
Got a question about this case?
Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.
⭐ Business Intelligence Access
See the full compliance picture for every pharma company
291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.
One real case. One key lesson. Every week — free.